Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Danaher Corp (DHR)

Danaher Corp (DHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Danaher Corporation's Q1 2026 Earnings Report

Washington, D.C.-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States and internationally. The company has a market cap of $135.3 billion and operates through Biotechnology, Life Sciences, and Diagnostics segments. 

DHR is expected to release its Q1 2026 earnings on Tuesday, Apr. 21, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $1.94 on a diluted basis, up 3.2% from $1.88 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.

Fundamentals

See More
  • Market Capitalization, $K 135,255,424
  • Shares Outstanding, K 707,699
  • Annual Sales, $ 24,568 M
  • Annual Income, $ 3,614 M
  • EBIT $ 4,690 M
  • EBITDA $ 7,137 M
  • 60-Month Beta 0.95
  • Price/Sales 5.50
  • Price/Cash Flow 16.78
  • Price/Book 2.56

Options Overview Details

View History
  • Implied Volatility 37.35% (+1.88%)
  • Historical Volatility 26.71%
  • IV Percentile 88%
  • IV Rank 39.58%
  • IV High 60.77% on 04/08/25
  • IV Low 22.02% on 12/24/25
  • Expected Move (DTE 4) 4.70 (2.45%)
  • Put/Call Vol Ratio 1.19
  • Today's Volume 434
  • Volume Avg (30-Day) 5,767
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 61,631
  • Open Int (30-Day) 65,534
  • Expected Range 186.80 to 196.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.94
  • Number of Estimates 10
  • High Estimate $1.98
  • Low Estimate $1.92
  • Prior Year $1.88
  • Growth Rate Est. (year over year) +3.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.01 +6.05%
on 03/27/26
199.38 -3.72%
on 03/09/26
-3.53 (-1.81%)
since 03/06/26
3-Month
181.01 +6.05%
on 03/27/26
242.80 -20.93%
on 01/22/26
-44.62 (-18.86%)
since 01/06/26
52-Week
171.00 +12.26%
on 04/09/25
242.80 -20.93%
on 01/22/26
+10.20 (+5.61%)
since 04/04/25

Most Recent Stories

More News
What to Expect From Danaher Corporation's Q1 2026 Earnings Report

Danaher Corporation is approaching its first-quarter earnings release in a few weeks, and Wall Street is forecasting a low single-digit percentage rise in earnings.

XLV : 146.11 (-0.48%)
$SPX : 6,594.15 (+0.17%)
MASI : 178.48 (-0.06%)
DHR : 191.69 (+0.30%)
3 Reasons to Avoid DHR and 1 Stock to Buy Instead

3 Reasons to Avoid DHR and 1 Stock to Buy Instead

DHR : 191.69 (+0.30%)
The Often-Missed Corner of Healthcare That Wall Street Is Loving

Makers of crucial lab equipment and materials for the healthcare industry play a vital, though often overlooked, role for some higher-risk companies.

A : 115.03 (-0.39%)
TMO : 484.92 (-1.33%)
DHR : 191.69 (+0.30%)
These 3 Defensive Stocks Just Hit 52-Week Highs — Should You Lock In Gains?

High PEG ratios indicate that many defensive stocks in health care and consumer staples trade at stretched valuations. With earnings growth lagging price momentum, three stand out as candidates for profit-taking...

DAR : 63.50 (-1.78%)
VLO : 244.24 (+0.06%)
MASI : 178.48 (-0.06%)
ETON : 25.06 (+0.28%)
DHR : 191.69 (+0.30%)
Spotting Winners: Danaher (NYSE:DHR) And Research Tools & Consumables Stocks In Q4

Spotting Winners: Danaher (NYSE:DHR) And Research Tools & Consumables Stocks In Q4

DHR : 191.69 (+0.30%)
Danaher Schedules First Quarter 2026 Earnings Conference Call

WASHINGTON , March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21,...

DHR : 191.69 (+0.30%)
Is Revvity Stock Underperforming the S&P 500?

Revvity has lagged the broader S&P 500 over the past year, though analysts maintain a cautiously positive outlook on its forward growth potential.

$SPX : 6,594.15 (+0.17%)
RVTY : 87.79 (-1.29%)
DHR : 191.69 (+0.30%)
1 S&P 500 Stock Worth Your Attention and 2 Facing Headwinds

1 S&P 500 Stock Worth Your Attention and 2 Facing Headwinds

NVDA : 176.50 (-0.50%)
KMB : 96.87 (+0.77%)
DHR : 191.69 (+0.30%)
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

DHR : 191.69 (+0.30%)
1 Profitable Stock to Target This Week and 2 We Avoid

1 Profitable Stock to Target This Week and 2 We Avoid

GPK : 9.60 (-0.83%)
IPAR : 89.34 (-1.40%)
DHR : 191.69 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of...

See More

Key Turning Points

3rd Resistance Point 199.75
2nd Resistance Point 196.77
1st Resistance Point 193.95
Last Price 191.69
1st Support Level 188.15
2nd Support Level 185.17
3rd Support Level 182.35

See More

52-Week High 242.80
Fibonacci 61.8% 215.37
Fibonacci 50% 206.90
Fibonacci 38.2% 198.43
Last Price 191.69
52-Week Low 171.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.